Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 15/20 | 0.60 |
| ▸ | IDH2 | P48735 | 4/20 | 0.49 |
| ▸ | TPH1 | P17752 | 1/20 | 0.41 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21378443 | 1.00 | IDH1 (0.60) | IDH1IDH2TPH1SCN5ASCN9A | |
| SCHEMBL21378349 | 0.88 | IDH1 (0.47) | IDH1IDH2 | |
| SCHEMBL21378348 | 0.88 | IDH1 (0.47) | IDH1IDH2 | |
| SCHEMBL21378439 | 0.87 | IDH1 (0.56) | IDH1IDH2ADORA2AADORA2B | |
| SCHEMBL19700702 | 0.87 | IDH1 (0.56) | IDH1IDH2ADORA2AADORA2B | |
| SCHEMBL21378370 | 0.85 | IDH1 (0.85) | IDH1IDH2 | |
| SCHEMBL21378371 | 0.85 | IDH1 (0.85) | IDH1IDH2 | |
| SCHEMBL21378456 | 0.79 | IDH1 (0.58) | IDH1IDH2 | |
| SCHEMBL21378455 | 0.79 | IDH1 (0.58) | IDH1IDH2 | |
| SCHEMBL20270979 | 0.77 | ACACB (0.47) | IDH1IDH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3464281-B1 | MUTANT IDH1 INHIBITORS | LILLY CO ELI (US) | 2020-07-08 | — | — | EP | disclosed |
| US-10696665-B2 | Mutant IDH1 inhibitors | ELI LILLY AND COMPANY (US) | 2020-06-30 | — | — | US | disclosed |
| US-20190292175-A1 | MUTANT IDH1 INHIBITORS | ELI LILLY AND COMPANY | 2019-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10696665-B2 | Mutant IDH1 inhibitors | IDH1, IDH3B, IDH3A | IDH1 1/4885IDH2 4/4885TPH1 4399/4885 |
| US-20190292175-A1 | MUTANT IDH1 INHIBITORS | IDH1, IDH3B, IDH3A | IDH1 1/4885IDH2 4/4885TPH1 4399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.